Skip to Highlights
Highlights

The President's Emergency Plan for AIDS Relief (PEPFAR) provides assistance for combating HIV/AIDS in 15 focus countries and elsewhere, with global targets for prevention, treatment, and care. The U.S. Leadership Against HIV/AIDS, TB and Malaria Act of 2003, which authorizes the $15 billion program, contains directives to guide the Office of the U.S. Global AIDS Coordinator's (OGAC) allocation of this funding. The act expires in September 2008. The President announced his intention to ask Congress to authorize $30 billion for these efforts for the next 5 years. In 2007, the Institute of Medicine (IOM) recommended eliminating the directives. GAO was asked to describe (1) the views of HIV/AIDS experts on these directives, (2) an alternative approach to allocating funds, and (3) potential challenges related to this approach. GAO interviewed 22 experts, surveyed PEPFAR officials in the 15 focus countries, and reviewed pertinent documentation.

Skip to Recommendations

Recommendations

Matter for Congressional Consideration

Matter Status
If Congress decides to remove the spending directives as IOM recommended, Congress may wish to encourage OGAC to adopt a more country-based and evidence-based approach to allocating funding, with OGAC providing overall leadership and guidance for setting country-specific targets, selecting interventions, and considering costs, as discussed in this report.
Closed - Implemented

Recommendations for Executive Action

Agency Affected Recommendation Status
Department of State 1. To help ensure that PEPFAR country teams are better able to provide consistent and accurate cost estimates to OGAC, the Secretary of State should direct OGAC to provide appropriate guidance to PEPFAR country teams for identifying and using cost-related information in planning and budgeting PEPFAR programs.
Closed - Implemented
State's Office of Global Aids Coordinator (OGAC) agreed with our recommendation to help provide consistent and accurate cost estimates to the field by strengthening guidance for identifying and using cost information for planning and budgeting. Specifically, State noted that PEPFAR already had a number of costing models in use, including a multi-country study that was being utilized in the development of a cost projection model for use by PEPFAR country teams to estimate resource needs for treatment, and indicated that OGAC could start to distribute guidance that sets minimum standards for cost analyses and also provide options for more intensive studies by fiscal year 2010. Indeed, in our non-audit review of costing models in October 2010 (GAO-11-64), we found that OGAC had developed and deployed the PEPFAR antiretroviral therapy (ART) costing model in four countries. Additionally, in December 2011, a briefing by the PEPFAR Finance and Economics Work Group

Full Report

GAO Contacts